- Home
- MDCX vs VANI Comparison
MDCX vs VANI Comparison
Compare MDCX & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- VANI
- Stock Information
- Founded
- MDCX 2008
- VANI 1998
- Country
- MDCX Canada
- VANI United States
- Employees
- MDCX N/A
- VANI N/A
- Industry
- MDCX
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MDCX
- VANI Health Care
- Exchange
- MDCX Nasdaq
- VANI Nasdaq
- Market Cap
- MDCX 36.2M
- VANI 75.8M
- IPO Year
- MDCX N/A
- VANI 2014
- Fundamental
- Price
- MDCX $2.48
- VANI $1.27
- Analyst Decision
- MDCX Strong Buy
- VANI Strong Buy
- Analyst Count
- MDCX 2
- VANI 1
- Target Price
- MDCX $23.50
- VANI $4.00
- AVG Volume (30 Days)
- MDCX 403.1K
- VANI 52.2K
- Earning Date
- MDCX 08-11-2025
- VANI 11-12-2025
- Dividend Yield
- MDCX N/A
- VANI N/A
- EPS Growth
- MDCX N/A
- VANI N/A
- EPS
- MDCX N/A
- VANI N/A
- Revenue
- MDCX N/A
- VANI N/A
- Revenue This Year
- MDCX N/A
- VANI N/A
- Revenue Next Year
- MDCX N/A
- VANI N/A
- P/E Ratio
- MDCX N/A
- VANI N/A
- Revenue Growth
- MDCX N/A
- VANI N/A
- 52 Week Low
- MDCX $1.79
- VANI $0.91
- 52 Week High
- MDCX $8.94
- VANI $1.80
- Technical
- Relative Strength Index (RSI)
- MDCX 58.75
- VANI 50.75
- Support Level
- MDCX $2.00
- VANI $1.19
- Resistance Level
- MDCX $2.11
- VANI $1.40
- Average True Range (ATR)
- MDCX 0.19
- VANI 0.07
- MACD
- MDCX 0.08
- VANI 0.01
- Stochastic Oscillator
- MDCX 87.34
- VANI 50.00
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.